Dendritic cells (DC) are the mononuclear cells that initiate adaptive immune responses. Osteoclasts (OC) are the multinucleated giant cells that resorb bone. As previously described for human conventional DC (cDC), we demonstrate that murine cDC, either in vitro generated from Fms‐like tyrosine kinase 3 (Flt3)⁺ bone marrow progenitors or ex vivo purified from spleen, are able to develop into OC in response to M‐CSF and receptor activator of NF‐κB ligand (RANKL) in vitro. This transdifferentiation is driven by the immune environment that controls cDC maturation, cell fusion, tartrate‐resistant acid phosphatase (TRAP) and bone resorption activities. Only immature cDC have the capacity to become OC since mature cDC or plasmacytoid DC do not. Additions of the pro‐inflammatory cytokines, such as IL‐1β and TNF‐α, or human rheumatoid synovial fluid, increase murine cDC transdifferentiation into OC, whereas IFN‐α inhibits it. The adaptive cytokine, IFN‐γ, inhibits cDC fusion while IL‐4 increases it. IL‐2, IFN‐γ and IL‐4 inhibit TRAP and bone resorption activities contrary to IL‐10, which enhances both activities. A putative new “immune multinucleated giant cell” unable to resorb bone, which is formed owing to IL‐4, is underlined. The future analysis of cDC transdifferentiation into OC in murine models of inflammatory arthritis will give us the quantitative importance of this phenomenon in vivo.